Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer – Pages 155-168

Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Pages 155-168

Palanisamy Sivanandy1, Suresh Shanmugam1, Rui Ying Lau2, Jonathan Yvong Syen Chin2, Xiao Xiang Lee2, Yun Yun Lau2, Wai Ching Lee2, Iqbal Danial Said2, Jing Ying Lee2 and Karthikayini Krishnasamy3

1Department of Pharmacy Practice, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia; 2School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia; 3Department of Nursing – Oncology Nursing, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

DOI: https://doi.org/10.29169/1927-5951.2020.10.04.5

Abstract: Breast cancer affect almost 1 in 8 women and it is highest in developed and developing countries. There are many drugs exist for the treatment of breast cancer, but still the incidence of mortality and morbidity are high among all cancer types in most countries. Even though the conventional therapies play a major role in the management of breast cancer, its complications are obvious and unavoidable. The newer targeted drug therapy came in place to reduce complications in some extent, but not fully. Hence, a review was aimed to analyse the efficacy and safety of newer anticancer drugs that approved for the treatment of breast cancer by US-FDA from 2017 to 2019. The Olaparib, Talazoparib, and Ribociclib are the newly approved drugs for the treatment of breast cancer during this review period. Among these new drugs, Olaparib and Talazoparib alone or in combination with other anticancer drugs considered as safe and efficacious. Patients with Olaparib or Talazoparib as monotherapy have median progression-free survival of 2.8 to 8.6 months longer and has 42-46% lower risk of death (P<0.001). A combination of conventional therapies and non-pharmacological approach are warranted for the best benefit of cancer patients and to improve their quality of life.

Keywords: Metastasis, olaparib, patient, talazoparib, therapy.